In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

King buys Lorabid from Lilly for $90.5mm, plus earnouts

Executive Summary

King Pharmaceuticals (inlicenser) bought rights in the US (Puerto Rico included) to Eli Lilly's antibiotic Lorabid (loracarbef) for an initial payment of $90.5mm, plus sales performance milestones. If the drug achieves annual net sales of $140mm, the total payment will be $158mm. King gets all of the drug's US patents, trademarks, INDs, and NDAs, and Lilly will keep manufacturing rights.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Product Purchase

Related Companies